Payment overview · 2025
General Payments
$1,097.49
51 reported records · 18 companies
Healthcare provider profile · identity verified
John T Shaw, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1245300391
Verified facts
What the public records show
CMS Open Payments records show John T Shaw, M.D. received $1,097.49 in general payments during 2025 across 51 reported records.
ABBVIE INC. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $182.79 | 16.7% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $152.61 | 13.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.58 | 12.7% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $120.72 | 11.0% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.60 | 5.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.06 | 5.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.92 | 5.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.81 | 4.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.82 | 4.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.98 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.51 | 3.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.62 | 3.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.55 | 2.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.34 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.92 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.50 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.88 | 1.4% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.28 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,097.49 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $152.61 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.58 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $110.25 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $110.25 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $86.56 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.01 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.54 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.60 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.92 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.81 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.81 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.82 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.51 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.16 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.55 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 81 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 96 |
| Omeprazole | Omeprazole | 264 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 76 |
| Lisinopril | Lisinopril | 178 | 58 |
| Trazodone Hcl | Trazodone Hcl | 176 | 48 |
| Metformin Hcl Er | Metformin Hcl | 165 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 54 |
| Gabapentin | Gabapentin | 163 | 49 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 160 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 48 |
| Celecoxib | Celecoxib | 138 | 50 |
| Alprazolam | Alprazolam | 137 | 37 |
| Meloxicam | Meloxicam | 136 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 39 |
| Montelukast Sodium | Montelukast Sodium | 123 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 33 |
| Losartan Potassium | Losartan Potassium | 118 | 39 |
| Telmisartan | Telmisartan | 117 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 44 |
| Eliquis | Apixaban | 106 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 104 | 32 |
| Furosemide | Furosemide | 102 | 30 |
| Irbesartan | Irbesartan | 100 | 28 |
| Clonazepam | Clonazepam | 99 | 20 |
| Ozempic | Semaglutide | 95 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 30 |
| Dutasteride | Dutasteride | 81 | 27 |
| Mounjaro | Tirzepatide | 81 | 17 |
| Bupropion Xl | Bupropion Hcl | 78 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 37 |
| Famotidine | Famotidine | 72 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 26 |
| Tramadol Hcl | Tramadol Hcl | 68 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 17 |
| Carvedilol | Carvedilol | 62 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 21 |
| Ondansetron Odt | Ondansetron | 61 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 21 |
| Ibuprofen | Ibuprofen | 60 | 21 |
| Spironolactone | Spironolactone | 59 | 18 |
| Ezetimibe | Ezetimibe | 58 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 56 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 14 |
| Pregabalin | Pregabalin | 51 | 16 |
| Allopurinol | Allopurinol | 50 | 15 |
| Azelastine Hcl | Azelastine Hcl | 50 | 26 |
| Xarelto | Rivaroxaban | 50 | 11 |
| Chlorthalidone | Chlorthalidone | 49 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 12 |
| Farxiga | Dapagliflozin Propanediol | 45 | 14 |
| Azithromycin | Azithromycin | 44 | 36 |
| Estradiol | Estradiol | 43 | 15 |
| Methylprednisolone | Methylprednisolone | 43 | 33 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Metformin Hcl | Metformin Hcl | 42 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 23 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 14 |
| Glimepiride | Glimepiride | 39 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 14 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 11 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Diazepam | Diazepam | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Prednisone | Prednisone | 26 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Atenolol | Atenolol | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Valium | Diazepam | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,097.49 · 51 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, Kerendia, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error